Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

NCT06971939 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

285

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Telangiectasia Type 2 (MacTel)

Interventions

COMBINATION_PRODUCT: NT-501/revakinagene taroretcel-lwey

Sponsor

Neurotech Pharmaceuticals